# Advanced Accelerator Applications (Novartis)

Source: https://nuclide.cc/companies/advanced-accelerator-applications/  
Nuclide record `advanced-accelerator-applications` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.

## Summary

Advanced Accelerator Applications, based in Saint-Genis-Pouilly, France, and founded in 2002, is the CERN spin-out that Novartis bought in 2018 for Lutathera, and it now makes Pluvicto and the Locametz and Netspot imaging kits. AAA developed Lutathera, or 177Lu-DOTATATE, and the Netspot gallium-68 DOTATATE kit before its 3.9 billion dollar acquisition, and as Novartis' radioligand unit it manufactures Locametz, the gallium-68 PSMA-11 kit, and Pluvicto and runs the Novartis radioligand production network in Europe and the United States. Nuclide links it to prostate cancer and neuroendocrine tumours, to PSMA PET, somatostatin receptor PET and beta-emitter radioligand therapy, and to Novartis. Whether its production network can meet demand as radioligand indications widen is the open question. Locametz and Pluvicto have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Saint-Genis-Pouilly
- Type: radiopharma
- Website: https://www.adacap.com

## Sources

- Official website: https://www.adacap.com

## Connected records

- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://nuclide.cc/technologies/sstr-pet/)
- drugs: [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://nuclide.cc/drugs/ga68-dotatate/), [Locametz (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/locametz/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- companies: [Novartis](https://nuclide.cc/companies/novartis/)
- trials: [A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.](https://nuclide.cc/trials/nct06247995/), [A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC](https://nuclide.cc/trials/nct05849298/), [A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer](https://nuclide.cc/trials/nct05658003/), [A Study of 177Lu-FAP-2286 in Advanced Solid Tumors](https://nuclide.cc/trials/nct04939610/), [A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/nct07047118/), [Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET](https://nuclide.cc/trials/nct06784752/), [Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET](https://nuclide.cc/trials/nct03972488/)
- fronts: [Radioligand therapy](https://nuclide.cc/fronts/f-radioligand-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/advanced-accelerator-applications.json